Moreover, patients treated with oxaliplatin who had high OCTN2 levels in the tumor tissue had a reduced risk of recurrence and a significantly longer survival time than those with low expression of OCTN2 in tumor tissue [120]. This evidence concerns the gene SLC22A5 and neoplasm.